

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Grossman Adam S</u> (Last) (First) (Middle) <u>C/O ADMA BIOLOGICS, INC.</u> <u>465 STATE ROUTE 17</u> (Street) <u>RAMSEY NJ 07446</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ADMA BIOLOGICS, INC. [ADMA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President & CEO
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/13/2014</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.0001 par value per share	08/13/2014		P		1,000	A	\$9.81 ⁽¹⁾	603,457 ⁽²⁾⁽³⁾	I	Please see footnote ⁽⁴⁾
Common Stock, \$0.0001 par value per share	08/14/2014		P		1,100	A	\$9.74 ⁽⁵⁾	604,557 ⁽²⁾⁽⁶⁾	I	Please see footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.80 to \$9.90 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on August 13, 2014.
- 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 21,500 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.70 to \$9.75 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on August 14, 2014.
- 22,600 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

/s/ Adam S. Grossman 08/15/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.